Following Its Major Regulatory Win, How Much Upside Does Biogen Have?
Biotech giant Biogen (NASDAQ: BIIB) can certainly testify to the truth of this piece of wisdom. After a long and arduous journey, the company recently received approval for its Alzheimer's disease (AD) drug aducanumab from the U.S. Food and Drug Administration (FDA); the medicine will be marketed as Aduhelm. The controversial decision will likely continue generating tons of headlines, but with this major win under its belt, how much upside can Biogen's shareholders expect?
